Genetic polymorphisms in the CYP3A4 gene can result in variable enzyme activity among individuals. Some polymorphisms lead to reduced or enhanced enzyme activity, affecting drug metabolism rates. This variability can influence individual responses to medications, necessitating personalized dosing strategies to minimize toxicity and optimize therapeutic outcomes.
